Class II antigens and disease susceptibility.
The role for HLA typing in autoimmune disease is changing with the recognition that HLA markers can identify patients with poor prognosis in some autoimmune disease. Aggressive therapeutic intervention in patients with such HLA prognostic markers has the potential to improve or prevent progressive disease outcomes in a select group of patients.
Nepom
G T
GT
Virginia Mason Research Center, University of Washington School of Medicine, Seattle 98101, USA.
D001172:Arthritis, Rheumatoid / Q000235:genetics / Q000628:therapy; D001327:Autoimmune Diseases / Q000235:genetics* / Q000628:therapy; D003922:Diabetes Mellitus, Type 1 / Q000235:genetics / Q000628:therapy; D004198:Disease Susceptibility / Q000628:therapy; D005819:Genetic Markers / Q000235:genetics; D020022:Genetic Predisposition to Disease; D000949:Histocompatibility Antigens Class II / Q000235:genetics*; D006801:Humans; D011379:Prognosis; D012307:Risk Factors
D005819:Genetic Markers; D000949:Histocompatibility Antigens Class II